Maia Biotechnology shares rise 7.54% intraday after publishing promising preclinical data in Nucleic Acids Research.

Maia Biotechnology, Inc. rose 7.54% in intraday trading, following the publication of preclinical data from its second generation ateganosine prodrugs platform in Nucleic Acids Research. The study, titled 'Novel Telomere-Targeting Dual-Pharmacophore Dinucleotide Prodrugs for Anticancer Therapy,' highlights MAIA’s lead ateganosine (THIO)-derived second-generation prodrugs as promising new molecules in its strategy for enhancing cancer treatment and overcoming drug resistance.